SCHEMBL7179652

SCHEMBL7179652

COc1cc(OC)c(PC(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c(OC)c1.[LiH]

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.40
MAPT P10636 2/20 0.40
LMNA P02545 1/20 0.40
ATM Q13315 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.40
MAOB P27338 2/20 0.39
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
TAS1R2 Q8TE23 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HTT P42858 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180569 0.85 MAPT (0.44) GAAMAPTLMNAATMSMN1; SMN2
SCHEMBL7187593 0.83 MAPT (0.48) GAAMAPTATMSMN1; SMN2KMT2A
SCHEMBL7730586 0.82 MAPK8 (0.32) LMNAKMT2AMEN1MRGPRX4MAOB
Lithium SCHEMBL7180579 0.82 MAPT (0.44) GAAMAPTLMNAATMSMN1; SMN2
SCHEMBL7177789 0.82 AKR1C3 (0.33) GAAMAPTLMNAATMSMN1; SMN2
SCHEMBL7180865 0.81 KCNK3 (0.43) LMNANPSR1KMT2AMEN1MRGPRX4
SCHEMBL7187115 0.81 RXRA (0.40) GAAMAPTKMT2AMEN1ALDH1A1
SCHEMBL7177796 0.81 HTT (0.39) KMT2AMRGPRX4KDM4EALDH1A1HTT
SCHEMBL7185394 0.81 ABCG2 (0.44) MAPTLMNASMN1; SMN2KMT2AMEN1
SCHEMBL7180361 0.81 ABCG2 (0.42) GAAMAPTATMSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 GAA 4753/4885MAPT 4870/4885LMNA 3241/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 GAA 4793/4885MAPT 4859/4885LMNA 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.